{"entity":{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","aka":[],"tldr":"MagnetisMM-3 is the pivotal study behind elranatamab's approval.","summary":"MagnetisMM-3, trial NCT04649359 sponsored by Pfizer and reported in 2023, is the pivotal single-arm study behind elranatamab's approval in relapsed or refractory myeloma after at least three prior lines in BCMA-naive patients. In 123 patients the response rate was 61 percent with complete response or better in 35 percent, progression-free survival was durable, and switching to every-two-week dosing after six months maintained responses. OnCo links it to multiple myeloma, elranatamab and the MagnetisMM-3 paper. Whether reduced dosing frequency lowers infection risk without losing efficacy is the open question its design raised.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT04649359","url":"https://clinicaltrials.gov/study/NCT04649359"}],"tags":[],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":["elranatamab"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04649359","phase":"2","setting":"Relapsed/refractory myeloma after ≥3 lines, BCMA-naive: elranatamab monotherapy","sponsor":"Pfizer","result":"ORR 61%.","started":"2021-02-02","startedType":"actual","yearReported":2023,"enrolled":123,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective response rate","primary":true,"unit":"%","arms":[{"name":"Elranatamab","n":123,"value":61}],"source":"https://doi.org/10.1038/s41591-023-02528-9"}]},"route":"/trials/magnetismm-3/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}],"paper":[{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/"}]}}